Oncology and Carcinogenesis articles for Shanghai Jiao Tong University (SJTU), China

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 211

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
13 6.11
Ultrasound-Triggered Localized Surface Plasmon Resonance Enhances Electron Transfer for Melanoma Sonodynamic Therapy 0.30
Muscle-Targeted Nanocomposite Therapy Alleviates Age-Related Sarcopenia via Antioxidant and Metabolic Reprogramming 0.05
Noncontact Environmental Radiation Sensitization via Photoresponse Processes Mediated by Nanostructured Ru-Based Photosensitizers with Near-Infrared Responsiveness 0.91
Cysteine Metabolism Reprogramming-Motivated Catalytic Immunotherapy for Orthopedic Biofilm Infections 0.57
Mitochondria-Targeted Dual-Ion Perturbator Amplifies Cuproptosis for Enhanced Melanoma Immunotherapy and Accelerated Postoperative Wound Healing 0.72
Efficiently Reversing Immunotherapy Resistance in Lung Cancer by an Inhalable 2D Molybdenum Disulfide T Cell Hyperactivation Platform 0.44
Immune-Modulating Dual-Targeted Nanomaterials for Low-Temperature Photothermal–Photodynamic–Chemodynamic Therapy of Osteosarcoma Targeting Tumor and Endothelial Cells 0.11
Chiral Artificial Antigen-Presenting Cells Enhancing Tumor Immunotherapy: Evasion of Macrophage Uptake through Inhibition of Serum Protein Corona Formation 0.80
Noninvasive Activation of Local and Systemic Immunity with a Sequential-Targeting Sonodynamic Nanovaccine to Treat Glioblastoma 1.00
Immuno-Initiator Rectifies Immunodeficiency to Restore Immune Function and Potentiate Immunotherapy against IDH Mutant Glioma 0.07
Overcoming Radiotherapy Resistance in Chordoma through the Synergistic Action of Selenium-Containing Nanoparticles and THZ1 0.05
A Multifaceted Nanodrug Disrupts the Copper–Iron Homeostasis to Enhance Cancer Radiotherapeutic Effect 0.67
Spatiotemporally Controlled Co-Treatment of Lung Cancer and Pulmonary Immune-Related Adverse Events by Inhalable Albumin-Chaperoned Ultrathin MnOsub2/sub Nanosheets 0.43
3 1.14
Glutathione-Depleting Mitochondria-targeting Nanodrugs for Stress Amplification and Immune Activation via Synergistic Photodynamic Therapy and Cuproptosis 1.00
Fluorinated Polymeric Nanoplatform Relieves Tumor Hypoxia and Enhances Chemo-Sonodynamic Therapy 0.03
Photosensitive calcium-based nanoinducer for NIR-triggered immunogenic cell death and anti-tumor immunity 0.11
5 1.75
“AND” Logic‐Gated MRI Nanoswitch in Response to Copper and Glutathione for Precise Diagnosis of Microtumors 0.11
Tripartite Cascading Functions of Ultrathin RhMo Nanozymes in Tumor Catalytic Therapy 0.05
Biomimetic Exosome‐Camouflaged pH‐Responsive Dendrimer Nanogels as a Therapeutic Vaccine Against Pancreatic Cancer Through Reprogramming of Multiple Cell Types 0.20
Biomimetic SIRPα–CAR Engineering for In Situ Macrophage Reprogramming and Potent Solid Tumor Immunotherapy 1.00
Zr-Based Metal–Organic Framework Dual-Sensitized by Carbon Dot Sonosensitizers and MnO2−x Nanozymes for cGAS-STING Activation Enhanced Sonocatalytic-Immunotherapy 0.39
8 0.66
Lipid Droplet-Targeted Biomimetic Liposomes Potentiate Chemo-Ferroptosis Therapy in Leukemia 0.07
Self-Assembled Two-Dimensional Chiral Meso-Topography Determines the Balance of Cellular and Humoral Immunity Against Tumors 0.06
An Intracellular Magnetic Micromotor Drives Spatiotemporal Mechano‐Immunotherapy 0.04
Nanozyme‐Based Biomimetic Intelligent Immune Organelles for the Treatment of Bladder‐Metastasized Tumors 0.07
A Noninvasive and Highly Effective Inhaled Nanovaccine Based on Natural Polysaccharide for Lung Cancer Treatment 0.03
A Dendritic Cell‐Nanogel Conjugate for Tumor‐Draining Lymph Node‐Specific PD‐L1 Blockade 0.14
Self‐Powered α Radionuclide Nanomedicine: Mitochondria‐Targeted Multimodal Energy Recycling for Amplified Radioimmunotherapy 0.13
A Smart DNA Nanoframework Enables Synergistic Photodynamic Therapy of Pancreatic Cancer 0.11
6 3.00
Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis 0.57
Fluorescent Affinity Probe for mTOR Protein Synthesized via Click Chemistry and Its Applications 1.00
Single-Cell Raman Spectroscopy Combined with Metabolomics Reveals Distinct Metabolic Profiles in Medulloblastoma Subtypes 0.67
Efficient and Sensitive Bisulfite-Free Methylation Detection Approach for Low-Abundance and Highly Fragmented cfDNA 0.27
Deciphering the Mechanism of Interactions between Polyubiquitin Chains and Caspase Activation and Recruitment Domains Using Protein–Polymer-Engineering-Assisted Native Mass Spectrometry 0.40
Ultrasensitive eccDNA Detection for Tumor Diagnostics by Using CRISPR/Cas12a-Coupled Nested PCR 0.09
6 1.41
Dual-Interface Nanopore Array Sensor Revealing the Synergistic Oscillations of Lactate Efflux in Cancer Cells 0.11
NIR‐II‐Photopyroelectric Catalysis for Immunoactivation/Ferroptosis Combined Therapy of Tumor 0.86
Simultaneously Enhancing NIR‐II Emission, Type‐I, and Type‐II Photosensitization Through Acceleration of Charge‐Separated‐State Formation for Tumor Phototheranostics 0.08
Superhydrophilic FeIV2MnII Nanocluster: A Combined Diagnostic and Therapeutic Agent 0.15
Dual‐Locked Polymeric STING Nano‐Agonist/Sonosensitizer Augments Spatiotemporally Controlled Cancer Sono‐Immunotherapy 0.10
Au6Cu2 Clusters with High Electron Affinity and Oxygen-Mimetic Properties for Hypoxic Tumor Radiosensitization 0.11
1 0.02
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.02
1 0.02
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.02
7 2.36
Targeting tumor-intrinsic STK40 induces immune vulnerability and drives T cell reinvigoration 0.78
Cancer stem cells orchestrate immune evasion through extracellular vesicle-mediated non-canonical signaling pathways 0.29
Candida albicans synergizes with Fusobacterium nucleatum in colorectal cancer progression via the Flo9-RadD interaction 0.78
Single-cell screens identify ADAM12 as a fibroblast checkpoint impeding anti-tumor immunity 0.20
Integrative proteogenomic analysis provides molecular insights and clinical significance in gallbladder cancer 0.05
TROP-2-targeted antibody-drug conjugate SHR-A1921 for advanced or metastatic solid tumors: A first-in-human phase 1 study 0.03
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers 0.24
7 3.22
ARID1A Mediates SWI/SNF-Independent Maintenance of Heterochromatin Architecture to Restrain Viral Mimicry and Immunogenicity in Colon Cancer 0.47
Targeting LRRC15 in Cancer-Associated Fibroblasts Modifies the Extracellular Matrix and Enhances Tumor Immune Responses to Suppress Lung Cancer Progression 0.13
GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis 1.00
KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma 0.22
Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion 0.74
FNDC4 Drives Metastasis and Immune Evasion in Pancreatic Cancer. 0.61
Targeting the SP/KLF Transcriptional Regulatory Network Synergizes with HDAC Inhibition to Impede Progression of H3K27M Diffuse Intrinsic Pontine Glioma 0.05
3 0.55
Farnesylation-driven KRAS phase separation promotes colon tumor growth 0.05
Extracellular GPX4 impairs antitumor immunity via dendritic ZP3 receptors 0.22
Cancer cells co-opt an inter-organ neuroimmune circuit to escape immune surveillance 0.28
2 1.01
UBE2O-mediated monoubiquitination licenses NLRP6 inflammasome activation in the intestine 0.21
Bacterial effector OspB hijacks apoptosis through peptide-bond recombination of BH3 domain proteins 0.80
1 0.02
Dual targeting of SLC25A51 and succinate dehydrogenase selectively depletes mitochondrial NAD+ to eradicate KRAS-driven AML 0.02
2 1.12
Engineered MSCs enable bone marrow-targeted immunomodulation 1.00
A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy 0.12
1 0.17
NIR-II photozymes with stoichiometric chemistry-regulated enzyocatalytic activities for multi-modal nanocatalytic therapy 0.17
2 1.54
Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy 0.75
CircRNA-encoded RIPK1-98 protein drives lung adenocarcinoma progression 0.79
1 0.85
Single-Cell Analysis of Chemotherapy-induced Remodeling Reveals CD276-driven Basal-like Chemoresistance in Pancreatic Cancer 0.85
6 1.83
<atl>iAcinetobacter baumannii/i promotes gastric cancer metastasis via NA-mediated NAD metabolism reprogramming and glycolytic activation</atl> 0.18
Prospective evaluation of radical surgery for adenocarcinoma of oesophagogastric junction: real-world insights from the CLAEG study 0.02
LY6D identifies persistent stem-like cells driving pancreatic tumourigenesis 0.83
<atl>iStreptococcus anginosus/i -derived methionine promotes gastric cancer progression</atl> 0.62
Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study 0.05
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma 0.13
5 1.77
Deep learning-assisted tumor radiomic dynamics on MRI predict pathological complete response in HCC undergoing immune-based therapy followed by hepatectomy. 0.09
An α-specific PI3K inhibitor improves chemotherapy efficacy by inhibiting hepatic stellate cell activation in liver cancer. 0.13
RIPPLY1 suppresses cancer cell stemness via targeting TBX19 in CTNNB1-mutated hepatocellular carcinoma. 0.67
Arid1a deficiency promotes hepatocyte hyperpolyploidy and drives intrahepatic cholangiocarcinoma in mice. 0.83
Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: A study based on single-cell and spatial transcriptomic sequencing. 0.05
1 0.01
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome 0.01
4 1.55
Transmembrane BAX inhibitor motif containing 1 Inhibition of lysosomal degradation of TGF-β receptor 1 suppresses cellular senescence and hepatocarcinogenesis 0.10
FBXO9 mediated the ubiquitination and degradation of YAP in a GSK-3β-dependent manner 0.40
Ubiquitin-specific protease 7-mediated stabilization of discoidin domain receptor 1 drives progression of TP53-Mutant cancers 0.05
The transcriptional regulator Sin3a activates CD44 and promotes collective luminal breast cancer cell migration 1.00
5 2.24
Therapy-induced cholesterol biosynthesis drives lung cancer dormancy and drug resistance 0.18
A HHEX/IKKα positive feedback loop promotes intestinal inflammation 1.00
Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progression 0.83
Non-canonical functions of UGT2B17 promote castrate-resistant prostate cancer progression 0.06
Mutations in spliceosomal gene SNW1 cause neurodevelopment disorders with microcephaly 0.16
2 0.50
Multicenter Cohort Study of Original or Substitute Systemic Therapy With or Without Brain Radiotherapy for Extensive-Stage Small Cell Lung Cancer With Brain-Only Progression After First-Line Treatment 0.22
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial. 0.28
2 0.35
HIF-1–mediated ISG20 expression promotes breast cancer stemness and immune evasion 0.04
Integrated screens identify AURKB dependency in advanced gastrointestinal stromal tumors 0.31
5 2.98
Postoperative MRD status Refines Recurrence Risk Stratification Beyond Pathologic Response After Neoadjuvant Chemoradiotherapy for ESCC 0.79
Pathologic complete response after neoadjuvant immunochemotherapy: Persistent recurrence risk highlights the need for stratified management 0.04
Lymph node dissection in neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter real-world study 0.15
Clinic-Radiologic Predictors of Pathological Characteristics in Pure Ground-Glass Nodules: Development and Validation of a Predictive Nomogram 1.00
A Pathologic Classification Approach in Esophageal Squamous Cell Carcinoma Following Neoadjuvant Immunochemotherapy: Distinguishing Postoperative Outcomes and Exploring the Potential Benefit of Adjuvant Therapy 1.00
8 1.91
Chirality-Driven Immune Checkpoint Modulation by Chiral Iridium(III) Nanoparticles 0.12
Divergent Syntheses of the Euphorbia Diterpenoids Pepluanol A and Pepluacetal 0.31
Development of Substrate-Directed Activity-Based Probes via Disulfide-Trapping for Site-Specific Interrogation of Nucleosomal Deubiquitination 0.10
A Spatially Controllable DNA Origami-Based T-Cell Cluster Engager for Precise Tumor Elimination 0.05
Controlled Electron Transfer: Implementing a Reservoir-Pump-Integrated Strategy to Develop a Type I Photosensitizer for Evoking Long-Term Tumor Immunological Memory 0.29
Sono-Destructive Polymeric Nanocapsules Enable Spatiotemporal Orchestration of DC-T Cell Crosstalk in Combined In Situ Vaccination and Cytokine Therapy 0.11
Engineering of Sono-Activatable Immunogels for Immunometabolism Disorder Normalization Therapy of Breast Cancer 0.04
Nanoparticles Selectively Regulate the Generation and Scavenging of Multiple Reactive Oxygen Species at Designated Locations and States 0.89
4 0.81
Time-dependent relationship between urinary biomarkers of nucleic acid oxidation and colorectal cancer risk 0.08
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.01
Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant 0.03
Accelerometer-derived concentrated physical activity pattern and mortality in cancer survivors: the UK Biobank accelerometry study 0.69
2 0.27
Endogenous YAP/TAZ partitioning in TEAD condensates orchestrates the Hippo response 0.14
Mediator regulates transcriptional termination through crosstalk with pre-mRNA 3′ end processing factors 0.13
5 0.61
Bismuthene-Based Nanoplatform for Synergistic Thermogenetic CRISPR and Photothermal Cancer Therapy 0.13
Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events 0.20
Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair 0.19
Synergistic Defect-Driven Chemocatalysis and Ultrasound-Activated Piezocatalysis by Two-Dimensional SnSe Nanosheets 0.05
Overcoming Epithelial–Mesenchymal Transition Challenges in Cancer Detection through a Dual-Targeting Strategy 0.04
2 0.16
Androgen activity in the male embryonic hindbrain drives lethal PFA ependymoma 0.01
Cell-free chromatin state tracing reveals disease origin and therapy responses 0.15
2 0.99
Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumour immunity 0.85
YAP maintains the dynamics of TDP-43 condensates and antagonizes TDP-43 pathological aggregates 0.14
3 0.55
Targeting thymine DNA glycosylase induces synthetic lethality in p53-deficient cancers 0.09
Unique gluing effect of ASXL1 K351 monoubiquitination stimulates the PR-DUB activity 0.14
Structural basis for E4 enzyme Ufd2-catalyzed K48/K29 branched ubiquitin chains 0.32
42 14.27
Diffusion attention expert model for predicting and semi-automatic localizing STAS in lung cancer histopathological images 0.06
Targeting arginine metabolism reverses bone immunosuppressive microenvironment and metastasis in -deficient triple negative breast cancer 0.08
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis 0.60
Oral delivery of enterocyte-mimetic butyrate-loaded nanoparticles repairs the gut barrier and inhibits growth of digestive system tumors 1.00
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases 0.09
Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial 0.08
HuR coordinates systemic aging through platelet infiltration 0.04
GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy 0.91
T-cell mesenchymal transition represents a potential pathogenic mechanism of female cancer-related lymphedema 0.14
ELMO2 is a therapeutic vulnerability in mesenchymal-like and drug-resistant non-small cell lung cancer 0.07
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer 0.07
VGLL4-driven TEAD4 multimerization orchestrates DNA binding and YAP recruitment 0.17
D-π-A sensitized carbon dots as long-lived type-I/Ⅱ photosensitizers for NIR-excited hypoxia-regulated photodynamic therapy 0.30
MYC-induced USP10 stabilizes SOX4 to promote thymocyte proliferation and leukemia onset in mice 0.04
Timosaponin AIII enhances CAR-T cell potency and prevents relapse through impairing CAR-Tregs 0.16
Structural and evolutionary insights into the eukaryotic RNase MRP ribonucleoprotein complex 0.83
Spatiotemporally engineered tumor-derived extracellular vesicle-based scaffold vaccine for personalized cancer immunotherapy 1.00
Inhibition of the cancer stem cell immune checkpoint SOAT1 suppresses regulatory T cell functions through a trans-cellular 20(S)-Hydroxycholesterol-GPR132 pathway in mice 0.04
Prussian blue nanoparticles targeting multiple PANoptosome-mediated PANoptosis for myocardial ischemia-reperfusion injury therapy 1.00
Cryo-EM structures of light chain fibrils from abdominal fat biopsies of multiple myeloma patients 0.25
Dalpicilib combined with cetuximab in patients with HPV-negative, anti-PD-1-resistant recurrent or metastatic head and neck squamous cell carcinoma: A phase II trial 1.00
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression 0.24
Multi-center multi-omics integration predicts individualized prognosis in medullary thyroid carcinoma 0.08
Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial 0.04
Design of precision therapeutics for a CKD risk allele by targeting Shroom3-Rock interaction 0.05
Intraperitoneal programming of tailored CAR macrophages via mRNA lipid nanoparticle to boost cancer immunotherapy 0.17
Stereotactic body radiotherapy with sintilimab and bevacizumab biosimilar in anti-PD-1 refractory hepatocellular carcinoma: the ReUNION-1 phase 2 trial 0.01
Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer 0.15
Targeting LRBA triggers CTLA4 degradation and antitumor immunity for cancer immunotherapy 0.30
N-terminal α-amino SUMOylation promotes phosphorylation-independent cofilin-1 translocation to the mitochondrial matrix and induces apoptosis 0.90
Apatinib plus ifosfamide and etoposide versus ifosfamide and etoposide in patients with advanced osteosarcomas (OAIE/PKUPH-sarcoma 11): a randomized phase II study 0.10
A multiplexed assay by self-assembled dual-target responsive DNA hydrogels for efficacy evaluation of immunotherapy 0.94
Targeting tumor-intrinsic BCL9 reverses immunotherapy resistance by eliciting macrophage-mediated phagocytosis and antigen presentation 0.05
Targeting polyamine metabolism and ferroptosis enhances the efficacy of KRAS-targeted therapy depending on KEAP1 status 0.03
αTIGIT-IL2 achieves tumor regression by promoting tumor-infiltrating regulatory T cell fragility in mouse models 0.08
Direct - mRNA interaction regulates cell proliferation and cancer progression 0.02
Integrative proteogenomic characterization of Wilms tumor 0.58
OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer 1.00
Explainable multimodal deep learning for predicting thyroid cancer lateral lymph node metastasis using ultrasound imaging 0.55
Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer 0.08
Distinct structural mechanisms of LGR4 modulation by Norrin and RSPOs in Wnt/β-catenin signaling 0.22
Dual asparagine-depriving nanoparticles against solid tumors 0.75
1 0.07
Single-cell multi-omic and spatial profiling of esophageal squamous cell carcinoma reveals the immunosuppressive role of GPR116+ pericytes in cancer metastasis 0.07
1 0.01
Inhibition of salt-inducible kinases reprograms T cells and antitumor immunity in ovarian cancer 0.01
2 0.06
The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial 0.03
CLDN18.2–targeting antibody–drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial 0.03
1 0.72
A peritumoral microenvironment engaged by Reg-EXTL3 axis fosters nerve-cancer interactions in pancreatic ductal adenocarcinoma 0.72
2 1.53
Sequential chemo-immunotherapy followed by standard versus reduced thoracic radiotherapy for older and/or frail stage III non-small-cell lung cancer: A randomized open-label cohort trial 0.60
Metabolomic insights into associations between adiposity markers and liver cancer risk: Results from a prospective cohort study and Mendelian randomization analysis 0.93
8 2.62
A CHKA–PML autophagy checkpoint enables tumors to evade glutamine starvation 0.19
A pharmacovigilance data–driven approach to reveal high fatal adverse events following checkpoint immunotherapy 0.61
ARP2/3 complex mediates the neuropathology of PTEN-deficient human neural cells downstream of mTORC1 and mTORC2 hyperactivation 0.09
HSCs/MPPs as cells of origin with altered differentiation hierarchy impairing immunomicroenvironment in PML::RARA and CBFα/β fusion AM 1.00
USP1–TRAF2 axis–regulated mortalin stability mediates chemoresistance by disrupting calcium transport in peripheral T-cell lymphoma 0.03
CRISPR screens identify the ATPase VCP as a druggable therapeutic vulnerability in cholangiocarcinoma 0.58
The pathogenic factor of ZC4H2-associated rare disorder is a postsynaptic regulator for synaptic activity and cognitive function 0.08
Fine structural design of 3βHSD1 inhibitors for prostate cancer therapy 0.03
9 5.10
Spliceosomal mutation drives melanoma tumorigenesis via lineage-specific RAS activation 0.75
Chronic stress disrupts hepatic homeostasis and accelerates liver cancer progression through ADRB2 signaling 0.36
Tissue-specific inflammation induces cell state plasticity with oncogenic addiction in mucosal melanoma 0.79
An electrophilicity-engineered magnetic sensor for MRI detection of dormant tumor cell clusters 0.67
STING stimulation via supramolecular prodrug hydrogel boosts innate-adaptive immune cross-talk to prevent glioblastoma recurrence 0.89
Oral delivery of aptamer-decorated SICTERS Raman probes for colonoscopy-guided resection and photothermal immunization of microtumors 1.00
Engineering noncovalent π-stacked organic framework for intrinsic near-infrared photoactivated drug delivery 0.05
HLF transactivates TFEB to promote gallbladder cancer stem cells’ self-renewal and determines tumor response to distinct therapies 0.10
In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy 0.50
5 1.73
Targeting RBPMS selectively eliminates FOXO1-mediated stem cell signatures in mouse models of acute myeloid leukemia 0.24
Phase separation–based HTS identifies cobimetinib as a YAP-TEAD inhibitor that suppresses hyperactivated YAP-induced cancer progression 0.39
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.25
OX40–heparan sulfate binding facilitates CAR T cell penetration into solid tumors in mice 0.72
Proteogenomic characterization reveals that lipid droplet formation promotes esophageal squamous cell cancer progression 0.13
1 0.10
<atl>Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in iEGFR-/i mutated non-small cell lung cancer: systematic review and network meta-analysis</atl> 0.10
5 0.22
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial 0.04
Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial 0.06
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial 0.04
Adagrasib versus docetaxel in KRAS G12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial 0.05
Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial 0.03
3 0.26
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial 0.19
Vebreltinib in MET amplification-driven advanced non-small-cell lung cancer (KUNPENG): a single-arm, multi-cohort, multicentre, phase 2 study 0.04
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial 0.02
5 0.16
Sacituzumab Tirumotecan in EGFR-TKI–Resistant, EGFR-Mutated Advanced NSCLC 0.03
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.05
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.02
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.04
1 0.04
CCCH-type zinc finger proteins are required for meiotic progression and RNA clearance in Arabidopsis 0.04

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.